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Introduction

Peto’s Paradox
Despite having 2000 times more cells than humans, blue whales have not been found to
have tumors, or cancer in general (Caulin & Maley, 2019). This suggests that blue whales have a
mechanism at suppressing cancer at least 2000 times more effective than humans. If an animal is
larger or lives for a longer time, that animal would have an increase in the number of cells
dividing. Under the assumption that all cells have equal risk of cancer, this would mean an
animal like a human would have more cancer than an animal like a rat. However, as shown in
figure 1 the observed cancer rate remains the same across animals with varying lifespans and
body mass. This variation in expected and observed cancer rate is the basis of Peto’s Paradox.
This is the phenomenon that larger animals like blue whales should have higher rates of
cancer when compared to a human due to their increased lifespan and bodymass, but that is not
what is observed. There are a multitude of possible explanations as to why this may occur, but
this paper seeks to specifically explore hypertumors and metabolism.

Figure 1*. This figure illustrates the expected rate of cancer vs. the observed rate of
cancer.
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Hypertumors
A possible explanation for the negative correlation between body size and rate of cancer
in animals is the ability of tumors to form cheater cells known as hypertumors which have not
yet been proven to exist. Hypertumors allow the size of the tumors to be maintained at sublethal
sizes. Clinical disease in humans was defined as reaching 1.2 kg in weight. In a study done by
Nagy (2004), the mathematical cell simulations showed hypertumors held a sublethal size for
years, while only a small portion of the simulated tumors would have been deemed as clinical
disease in humans. Hypertumors are theorized to be “cheater cells” because they develop and
proliferate within a pre-existing tumor, depleting the original tumor’s resources and blood
supply. This trend can be seen in Figure 2 that depicts the decrease and eventual extinction of
hypertumor 1’s growth mass as hypertumor 2 begins to form. The formation of hypertumors
would deplete the original tumor of its blood supply and nutrients, leading to spontaneous cell
death. The hypertumor would no longer have a source of nutrients and die as well. It is
postulated that the common phenomenon of spontaneous necrosis or apoptosis in malignant
tumors, such as those seen in some neuroblastomas, could actually be the formation of
hypertumors (Nagy, 2004).

Figure 2*. This figure illustrates the growth rate of hypertumors.
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Neuroblastomas
The progression of how neuroblastoma development can be compared to the
hypothesized formation of hypertumors. Neuroblastomas are the second most common
malignant tumor in childhood. Children with this disease have a poor prognosis with the 5-year
survival rate being less than 60% (Garaventa et.al., 2003). Even with intense chemoradiotherapy,
children have a high fatal relapse rate and long-term survival rate of merely 25%. Little
improvement in prognosis has been made by additional treatments such as cytokines,
monoclonal antibodies, and radioactive metabolic drugs (Garaventa et.al., 2003). In its natural
course, neuroblastomas have been observed to go through spontaneous regression, a
characteristic expected to be seen in hypertumors. For this reason, it is hypothesized that
neuroblastomas are a form of hypertumors. It has also been noted that neuroblastomas that
exhibit overexpression of the RAS g-protein, a well-known oncogene, show morphological
changes indicative of cell death, another feature found in hypertumors (Nagy, 2004).
Metabolism
One of the pathways that has been studied in metabolism is the increase of reactive
oxygen species (ROS). This includes hydrogen peroxide (H2O2) and a number of free radicals.
ROS are highly reactive intracellular chemical species and are derivatives of O2. ROS also plays
an important role in metabolism, including regulation of apoptosis and vascular cell proliferation.
ROS are byproducts of metabolism and can cause DNA damage which can lead to aging and
cancer. Elevated ROS levels can lead to pathologic conditions, including tumor growth as well as
spontaneous cell death, a characteristic of hypertumors (DeBerardinis and Chandel, 2016).
Larger animals have lower basal metabolic rate (BMR), indicative of the amount of oxidative
damage which is also low in large animals (Caulin and Maley, 2011). This leads to less
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endogenous DNA damage and somatic mutation rates, decreasing the rates of cancer before it
even forms (Caulin and Maley et.al., 2011). However, it is now accepted that moderate levels of
ROS are needed for many cellular functions.

How Hypertumors Explain Peto’s Paradox

Characteristics of Hypertumors
If hypertumors were witnessed in a clinical setting spontaneous cell death of portions of a
tumor would be visible. This may present itself as necrosis or large regions of apoptosis, a cause
of which may be disruption of the tumor's blood supply without further explanation. This
spontaneous cell death is linked to the overexpression of the RAS g-protein which is associated
with the activation of the JNK and p38 MAPK pathways (Wagner and Nebreda, 2009). These
characteristics are present in neuroblastomas making them a target of research as possible
hypertumors. An anticancer drug, Fenretinide, is used to treat neuroblastomas and also induces
overexpression of RAS. Depending on the pathway and dosage taken, this can lead to cell death
or cancer further providing evidence for the existence of hypertumors.

RAS and JNK/p38
The RAS g-protein activates the JNK and p38 MAPK pathways which are integral in the
control of cell proliferation and differentiation by regulating cell cycle progression. In particular,
the JNK and p38 MAPK pathways are associated with cancer growth in humans.
JNK’s role in cell cycle progression and cell growth has been well defined, however, the
pathway has yet to be fully realized. JNK can initiate cell growth and survival by being activated
transiently, however, its prolonged activation leads to necrosis that will be seen in the mechanism
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for fenretinide (Maurer et.al., 1999). One possible pathway for prolonged JNK activation
involves the mediation of the tumor necrosis factor-α (TNFα)-dependent apoptosis in a
caspase-dependent manner, more specifically the caspase 8 activation pathway. Further, the
second possible pathway for JNK works in a caspase-independent manner by inhibiting the
caspase 8 pathway. This pathway involves E3 ubiquitin ligase iTCH which leads to the inhibition
of the caspase pathway and FADD-like apoptosis regulator through JNK1, a MAPK,
phosphorylation of iTCH31. The JNK1 pathway involves the regulation of proteins p53,
activating transcription factor 2 (ATF2), and ElK1. The third possible mechanism involves the
tumor necrosis factor-α (TNFα)-dependent apoptosis and caspase 8- independent cleavage of
BH3-interacting domain death agonist (BiD). The purpose of this is to relieve the inhibition on
caspase 8 (Wagner and Nebreda, 2009).

Figure 3*. The possible JNK pathways.
In contrast to the JNK pathway, the p38 MAPK pathway has been established with a
special focus on p38α. Currently, it has been discovered that there are four genes that encode for
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the p38 MAPK pathway, including MAPK14 encoding for p38a, which is the most researched
and highly abundant (Wagner and Nebreda, 2009). This pathway is activated by upstream MKK3
and MKK6 kinases as shown in the Figure 4. The major proteins of interest that are regulated by
this pathway include p53, ATF2, and ElK1. It should also be noted that these are the same
proteins regulated by the JNK1 pathway as well. This pathway, like the JNK pathway, can
increase tumor growth and promote angiogenesis of a tumor. However, under correct conditions
such as activation due to MKK6, the p38 pathways have been shown to suppress tumor
metastasis. In addition, it has been shown that apoptotic stimuli can activate p38α. This has been
linked to the production of ROS and is likely important to p38a tumor suppression. In
immortalized cells, p38α triggers apoptosis in response to increased expression of ROSinducing oncogenes.

Figure 4. The p38 MAPK Pathway (Wagner et al., 2009)
Sustained activation of the JNK and p38 MAPK has been shown to induce cell death.
These pathways can be activated by a number of stimuli including oxidative stress and chemical
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agents. In KP-N-TK (neuroblastoma) cells, the RAS g-protein activates these pathways in an
ROS-dependent manner.

Neuroblastomas
Neuroblastomas exhibit characteristics seen in mathematical models of hypertumors
including programmed cell death and overexpression of the RAS g-protein (Nagy, 2004).
Research has examined the role of RAS in tumor regression, showing high expression of RAS in
favorable outcomes (Kitanaka et al., 2002). Degenerating tumor cells also showed nuclear
condensation, no activation of caspase cascade, and no apoptotic DNA fragmentation. This
means neuroblastoma cells with overexpression of RAS follow a caspase-independent,
non-apoptotic cell death. It was also tested and confirmed that autophagic degeneration, a
nonapoptotic type of programmed cell death, can be induced by RAS overexpression. Thus,
increased levels of RAS have been correlated to aggressive cell proliferation which may be
causing the spontaneous regression seen (Kitanaka et.al., 2002). For this reason, neuroblastomas
and their mechanisms are being further studied to determine correlation to the possible existence
of hypertumors.

Fenretinide
N-(4-Hydroxyphenyl)- retinamide (4HPR), commonly known as Fenretinide, is a retinoid
anti-cancer drug that has been recently studied in correlation to the treatment of neuroblastomas.
Fenretinide induces apoptotic cell death in neuroblastoma cells. Studies have shown that this
occurs due to sustained activation of the p38 MAPK and JNK pathways of the RAS g-protein in
an ROS-dependent manner. In resistant neuroblastoma cells, Fenretinide did not produce
intracellular ROS and thus activated the kinase pathways. (Osone et.al., 2004).
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Retinoids have been researched extensively in vitro regarding neuroblastomas and in
recent years have been used in clinical investigation. In vitro studies demonstrated that
Fenretinide can suppress malignant tumor growth associated with induced apoptosis (Lovat
et.al., 2000). This includes neuroblastomas, and it is believed that administration of this drug
over a long period may prevent relapse of the disease. This is essential in neuroblastoma patients,
where the high rate of relapse can be fatal. In a phase I drug trial, disease progression was also
measured and showed signs of disease stabilization. In addition, the majority of patients had
manageable, reversible toxicities showing promise for the clinical use of the drug. This is
indicative that Fenretinide has the potential to provide prolonged stabilization within
neuroblastoma patients and should be further researched.

Metabolism is Another Pathway of Peto’s Paradox

ROS
Fenretinide has multiple distinct pathways that allow it to induce apoptosis. One of the
pathways that have been studied is the increase of ROS (Lovat et.al., 2000). In humans, moderate
to low levels of ROS are needed for many cellular functions. Elevated ROS levels can be seen in
tumor cells and can lead to increased tumor growth. Paradoxically, once a toxicity threshold of
ROS levels is reached, this triggers apoptosis of cancer cells, as seen in Fenretinide, without
affecting normal cells. The effect of ROS levels is shown in Figure 5. A decrease in ROS levels
would lead to less formation of cancer, but if cancer were to form it would lead to an adapted
cancer cell that can survive in lower ROS conditions. An increase in ROS levels above optimal
range for cancer cells would lead to cancer cell death.Therefore, manipulating ROS levels can be
used to treat cancer (DeBerardinis and Chandel, 2016).
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Figure 5*. This figure illustrates the effect of a decrease and increase in ROS levels.

Previous studies claimed that metabolism and hypertumors were two different pathways
that serve to explain Peto’s Paradox, however, given the literature review in this paper, it can be
hypothesized that the effects of metabolism and the existence of hypertumors are linked via
ROS. Despite low levels of ROS being optimal for both large animals and humans, higher levels
of ROS above the normal level has been shown to be beneficial. The trials involving Fenretinide
support this (Perillo et al., 2020).

Redox
Reactive Oxygen Species include hydrogen peroxide (H2O2) and a number of free
radicals. One of the ways metabolism controls signaling is by manipulating ROS levels. Low
levels of ROS are integral to basic cell function, cell proliferation and cellular adaptation due to
metabolic stress. In cancer cells, H2O2 levels increase. This leads to activation of signaling
pathways and conversion of H2O2 to OH radicals, which directly damage DNA, proteins, and
lipids (DeBerardinis and Chandel, 2016). In addition, signaling pathways and transcription
factors necessary for tumorigenesis are activated. This is done by activation of oncogenes, and
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by losing tumor suppressors. Cancer cells need increased ROS levels, but substantially increased
levels of ROS can lead to spontaneous cell death. Increased ROS levels can be induced by
disabling the antioxidant capacity of cancer cells which allows ROS levels to rise and induce
cancer cell death. To prevent this from happening, cancer cells induce the NRF2- dependent
genes. In other words, this gene acts as a redox balance for cancer cells, making sure ROS levels
stay within an optimal range for proliferation (DeBerardinis and Chandel, 2016).

Discussion/Conclusion

Figure 6. This flowchart illustrates the connection made throughout this paper in a
consolidated manner.

In this paper, we postulate that the formation of hypertumors leads to overexpression of
the RAS g-protein, ultimately causing spontaneous cell death. In the study done by Kitanaka
(2002), it was stated that hypertumors would be expressed as regions of spontaneous cell death,
something that is seen in neuroblastomas (Kitanaka et. al., 2002). Further research provides
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evidence that the cause of this cell death is due to overexpression of the RAS g-protein leading to
sustained activation of the JNK and p38 MAPK pathways in an ROS dependent manner (Osone
et.al., 2004). If ROS levels increase beyond the optimal range, the cancer cells try to regulate it
by using NRF2 - dependent genes, and the cells die as a result. In this case, ROS levels rose too
high leading to cell death. However, lower ROS levels can prevent oxidative and DNA damage
beforehand, leading to less cancer overall. The metabolism standpoint serves to explain that
larger animals have lower BMRs and thus ROS, leading to less overall rates of cancer. Based on
these connections, we believe hypertumors follow a similar pathway to that of Fenretinide in
which it leads to over expression of the RAS g - protein in the original tumor. This results in cell
death alongside depleting the original tumor of its blood supply.
Not only does the existence of hypertumors serve as a possible explanation for Peto’s
Paradox, but the similarities in mechanisms involved in hypertumors, fenretinide and metabolism
serve as a basis for treatment of neuroblastomas and potentially other aggressive cancers.
However, it is important to note that hypertumors and metabolism are not the only possible
explanations for Peto’s Paradox. It could also be an adaptation of highly advantageous
characteristics, or evolution. The increased number of cells and mutations led whales to have an
increased number of p53 genes also known as tumor suppressor genes (Tollis et al., 2017). The
solution to Peto’s Paradox could be hypertumors, evolution or both.
Hypertumors stall the progression of cancer growth, lengthening the original prognosis
for many cancer patients. Since the stage of cancer at diagnosis is one of the most significant
prognostic factors, the stabilization of cancer growth may result in better outcomes than the
current methods used to approach cancer treatment. This paper strongly support further research
into the existence of hypertumors and their potential use against cancer growth. This includes
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drug trials of Fenretinide for treatment of neuroblastomas and further investigating into the
sustained activation of the JNK and MAPK pathways in an ROS dependent manner.
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